- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17.12.24 | Best practices in linguistic validation of clinical outcomes assessments | ||
| 16.12.24 | AbbVie's Parkinson's disease candidate tavapadon shows promise in phase 3 trial | ||
| 16.12.24 | Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer | ||
| 16.12.24 | Tackling the growing burden of chronic obstructive pulmonary disease in the UK | ||
| 16.12.24 | Over 40 years of Ipsen in the UK: resilience and leadership in the life sciences sector | ||
| 13.12.24 | Eli Lilly announces $3bn expansion to US injectables manufacturing facility | ||
| 13.12.24 | NICE recommends Santhera's Duchenne muscular dystrophy drug Agamree | ||
| 13.12.24 | Amar Urhekar announced as CEO of Avalere Health | ||
| 12.12.24 | AstraZeneca's Imfinzi granted FDA approval in limited-stage small cell lung cancer | ||
| 12.12.24 | Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines | ||
| 11.12.24 | GSK gains exclusive option on DualityBio's preclinical ADC in deal worth over $1bn | ||
| 11.12.24 | Merck and Ridgeback initiate phase 3 study of COVID-19 oral antiviral in high-risk adults | ||
| 10.12.24 | J&J presents positive phase 3 results for Darzalex Faspro in smouldering multiple myeloma | ||
| 10.12.24 | Roche announces five-year results for Polivy combination in diffuse large B-cell lymphoma | ||
| 09.12.24 | Sanofi's rilzabrutinib shows promise in phase 3 immune thrombocytopenia study | ||
| 09.12.24 | Regeneron shares positive late-stage results for poze-cemdi in rare blood disorder PNH | ||
| 06.12.24 | Sanofi unveils plans to build €1bn insulin production base in China | ||
| 06.12.24 | Amgen announces $1bn investment to establish new US drug manufacturing facility | ||
| 05.12.24 | GSK and Rgenta to develop RNA-targeting small molecules in deal worth up to $500m per target | ||
| 05.12.24 | LEO Pharma's Anzupgo cream granted MHRA approval to treat chronic hand eczema | ||
| 05.12.24 | ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients | ||
| 05.12.24 | AstraZeneca appoints Iskra Reic as executive vice president international | ||
| 04.12.24 | Ipsen enters $610m licensing deal with Biomunex to advance MAIT-cell engager | ||
| 04.12.24 | NICE recommends Immunocore's Kimmtrak as first drug for aggressive eye cancer | ||
| 04.12.24 | Best practices for conquering data management challenges in the pharma industry |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
